Recurrent congenital toxoplasmosis in a woman with lupus erythematosus.
We describe the case of a patient with systemic lupus erythematosus, treated by corticosteroids, who presented during two successive pregnancies with serological reactivation of toxoplasmosis associated with fetal lesions. The first infected fetus died in utero with signs of hydrops. The second fetus was treated in utero with a combination of sulfadoxine and pyrimethamine, administered to the mother, and is now well. The increasing number of immunocompromised pregnant patients with immunity to Toxoplasma gondii may lead to a higher risk of reactivation of maternal toxoplasmosis and congenital infection.
D'Ercole
C
C
Service de Gynécologie-Obstétrique B, Hôpital de la Conception, Marseille, France.
Boubli
L
L
Franck
J
J
Casta
M
M
Harle
J R
JR
Chagnon
C
C
Cravello
L
L
Leclaire
M
M
Blanc
B
B
D000328:Adult; D000653:Amniotic Fluid / Q000276:immunology; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000913:Antibodies, Protozoan / Q000032:analysis / Q000097:blood; D005260:Female; D005315:Fetal Diseases / Q000188:drug therapy; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007231:Infant, Newborn; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D011239:Prednisolone / Q000627:therapeutic use*; D011247:Pregnancy; D011248:Pregnancy Complications; D015597:Pregnancy Complications, Parasitic; D011739:Pyrimethamine / Q000627:therapeutic use; D013413:Sulfadoxine / Q000627:therapeutic use; D014122:Toxoplasma / Q000276:immunology; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy / Q000276:immunology*
D000890:Anti-Infective Agents; D000913:Antibodies, Protozoan; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D013413:Sulfadoxine; D011239:Prednisolone; D011739:Pyrimethamine